Drugs / BI 3819026
last change May 2026 re-read 2 minutes ago

BI 3819026

Developed for
metastatic malignant neoplasm
Investigated by
Boehringer Ingelheim

Trials 1 · a red edge is where a trial was stopped

20272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT07607678 May 2026 → Jun 2028 expected metastatic malignant neoplasm Boehringer Ingelheim Recruiting No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as BI 3819026 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07607678